Product Program year 2025 Source: CMS Open Payments

Zevtera

Drug Infectious Disease

NDC 68547-578-10

Open in the dashboard

General payments

$190,481

1,067 payments

Research payments

$0

0 payments

Through program year 2025, $190,481 in general payments and $0 in research payments were reported against Zevtera (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $190,481 1,067

Breakdown

Who paid General payments · program year 2025
  1. La Jolla Pharmaceutical Company $190,481 1,067 payments
Top recipients General payments · program year 2025
  1. Samir Awad Surgical Critical Care · Houston, TX $19,565 10% · 17 payments
  2. Javeed Siddiqui Infectious Disease · Roseville, CA $18,329 10% · 17 payments
  3. Juan Diaz Infectious Disease · Altamonte Springs, FL $14,125 7% · 16 payments
  4. Kamal Hamed Infectious Disease · East Hanover, NJ $12,100 6% · 4 payments
  5. Michael Gelfand Infectious Disease · Memphis, TN $11,363 6% · 14 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Infectious Disease Internal Medicine $132,427 71% · 303 practitioners
  2. Surgical Critical Care Surgery $19,565 11% · 1 practitioner
  3. Internal Medicine $17,325 9% · 101 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $2,623 1% · 53 practitioners
  5. Critical Care Medicine Internal Medicine $2,307 1% · 10 practitioners

The top 5 of 46 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $46,143 24% · 66 recipients
  2. Texas $38,734 20% · 73 recipients
  3. Florida $24,319 13% · 79 recipients
  4. Kentucky $20,320 11% · 30 recipients
  5. Tennessee $13,217 7% · 45 recipients

The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

1,067 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record